lazertinib,pemetrexed,amivantamab,osimertinib,carboplatin
astrazeneca,yuhan corp,genmab,janssen
['chrysalis-2', 'lcsm,(-blcsm)', 'amivantamab', 'biomarker', 'lazertinib', 'osimertinib']
#asco23 abs9013 chrysalis-2: amivantamab+lazertinib in post-osimertinib, chemo-na ve #egfr #lcsm n=101 , ihc-based met found predictive for response met+ orr 61% vs met- 12% no predictive biomarkers via ctdna ngs 
Fellow @MayoHemeOnc | @UConnIM| @UTexasSPH| @MDAndersonNews|@COVID19nCCC| #SoMeEditor @JCOCCI_ASCO| Co-Host @HemOncFellows @LungCancerRX https://t.co/dsiuV460lQ